Intended for UK Healthcare Professionals. This website contains promotional content.
Intended for IE Healthcare Professionals. This website contains promotional content.
Report adverse events
EPC® sofosbuvir/velpatasvir 400 mg/100 mg and 200 mg/50 mg coated tablets
VSV® sofusbivir/velpatasvir/voxilaprevir
HVN® ledipasvir 90 mg/sofosbuvir 400 mg tablets
HPX® ▼ bulevirtide 2 mg

Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page. HEPCLUDEX® (bulevirtide)▼ is subject to additional monitoring

  1. Home >
  2. Medicines
EPC sofosbuvir/velpatasvir 400 mg/100 mg and 200 mg/50 mg tablets

Discover EPCLUSA®

EPCLUSA® is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older.

Learn more

VSV® sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg tablets

Discover VOSEVI®

VOSEVI® is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg.

Learn more
HVN® ledipasvir 90 mg/sofosbuvir 400 mg tablets

Discover HARVONI®

HARVONI® is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above.

Learn more

UKI-EPC-0037

Date of preparation April 2025